ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Epic Medical Research Joins hyperCORE International's Global Partner Site Network

Epic expands hyperCORE's U.S. footprint with multi-state capabilities, advanced Phase I infrastructure, and deep expertise across high-demand therapeutic areas

LAKE MARY, FL, August 05, 2025 /24-7PressRelease/ -- hyperCORE International is pleased to welcome Epic Medical Research, based in Dallas, Texas, to its global partner site network, as the clinical research organization continues to expand its expansive footprint and capabilities through strategic partnerships.

Epic Medical Research operates across 12 state-of-the-art locations in four states, offering full-spectrum clinical trial capabilities across a broad range of therapeutic areas—including metabolic disorders, fatty liver disease (NASH), sleep apnea, obesity, endocrine disorders, pulmonary and gastrointestinal diseases, neurological and psychiatric conditions, pediatrics, rheumatology, dermatology, podiatry, and infectious diseases. With two advanced Phase I units, an on-site sleep lab, and a dedicated laboratory for end-to-end PBMC processing, Epic provides the infrastructure and scientific expertise required to support trials from early development through late-phase execution.

"Joining hyperCORE International marks a transformative step forward for Epic Medical Research," shared Dr. Haresh Boghara, President & Principal Investigator at Epic. "We are thrilled to be part of a collaborative network that shares our commitment to advancing clinical research and improving patient outcomes. By aligning with hyperCORE, we gain access to greater resources, shared expertise, and a broader platform to deliver high-quality, efficient, and innovative clinical trial solutions."

"Epic Medical Research brings an impressive combination of therapeutic breadth and operational scale to our global site network," said Nicholas Focil, President of hyperCORE International and CEO at FOMAT Medical Research, also part of the hyperCORE partner site network. "Their deep commitment to quality and innovation aligns perfectly with hyperCORE's mission to provide elevated trial performance across our collaborative network of clinical research partners. We're proud to welcome Epic as a partner and look forward to the collaborative impact we'll make together in delivering streamlined operations and accelerated results across clinical research."

Founded in 2019, hyperCORE International is a partner site network of leading clinical research site organizations. Boasting over 80 active trial sites across five countries and two continents, hyperCORE's partners have jointly completed 7,000+ studies involving over 140,000 randomized participants. Each partner member operates independently but integrates harmonized operational frameworks to optimize efficiency, standardization, and excellence.

hyperCORE remains committed to advancing clinical research through safe, ethical, timely studies; efficient enrollment; and superior retention—empowered by its members' top-tier awards for performance, quality, and innovation.

---
Press release service and press release distribution provided by https://www.24-7pressrelease.com
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.